{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T03:53:56Z","timestamp":1791258836905,"version":"4.1.0"},"reference-count":57,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82470186"],"award-info":[{"award-number":["82470186"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Leukemia Research"],"published-print":{"date-parts":[[2026,12]]},"DOI":"10.1016\/j.leukres.2026.108334","type":"journal-article","created":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T06:31:59Z","timestamp":1790836319000},"page":"108334","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Advances in diagnosis and treatment of angioimmunoblastic T-cell lymphoma"],"prefix":"10.1016","volume":"171","author":[{"given":"Qiuyan","family":"Lin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lei","family":"Fan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haorui","family":"Shen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.leukres.2026.108334_bib1","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2025.1479179","article-title":"Advancing the understanding and management of angioimmunoblastic T-cell lymphoma: insights into its pathogenesis, clinical features, and emerging therapeutic strategies","volume":"15","author":"Xing","year":"2025","journal-title":"Front. Oncol."},{"issue":"10","key":"10.1016\/j.leukres.2026.108334_bib2","doi-asserted-by":"crossref","first-page":"2592","DOI":"10.1038\/s41375-020-0990-y","article-title":"Advances in understanding of angioimmunoblastic T-cell lymphoma","volume":"34","author":"Chiba","year":"2020","journal-title":"Leukemia"},{"issue":"10","key":"10.1016\/j.leukres.2026.108334_bib3","doi-asserted-by":"crossref","DOI":"10.3390\/cancers14102392","article-title":"Novel T Follicular Helper-like T-Cell Lymphoma Therapies: From Preclinical Evaluation to Clinical Reality","volume":"14","author":"Krug","year":"2022","journal-title":"Cancers (Basel)"},{"issue":"1","key":"10.1016\/j.leukres.2026.108334_bib4","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1111\/bjh.16428","article-title":"The new biology of PTCL-NOS and AITL: current status and future clinical impact","volume":"189","author":"Timmins","year":"2020","journal-title":"Br. J. Haematol."},{"issue":"6","key":"10.1016\/j.leukres.2026.108334_bib5","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1007\/s11899-019-00545-5","article-title":"Targeting the JAK\/STAT Pathway in T Cell Lymphoproliferative Disorders","volume":"14","author":"Shouse","year":"2019","journal-title":"Curr. Hematol. Malig. Rep."},{"issue":"11","key":"10.1016\/j.leukres.2026.108334_bib6","doi-asserted-by":"crossref","first-page":"1490","DOI":"10.1182\/blood-2016-02-698977","article-title":"Activating mutations in genes related to TCR signaling in angioimmunoblastic and other follicular helper T-cell-derived lymphomas","volume":"128","author":"Vallois","year":"2016","journal-title":"Blood"},{"issue":"23","key":"10.1016\/j.leukres.2026.108334_bib7","doi-asserted-by":"crossref","first-page":"1940","DOI":"10.1038\/s41388-023-02699-2","article-title":"DNMT3AR882H accelerates angioimmunoblastic T-cell lymphoma in mice","volume":"42","author":"Zheng","year":"2023","journal-title":"Oncogene"},{"issue":"9","key":"10.1016\/j.leukres.2026.108334_bib8","doi-asserted-by":"crossref","first-page":"1014","DOI":"10.1038\/ng.3610","article-title":"DNMT3A and TET2 compete and cooperate to repress lineage-specific transcription factors in hematopoietic stem cells","volume":"48","author":"Zhang","year":"2016","journal-title":"Nat. Genet."},{"issue":"3","key":"10.1016\/j.leukres.2026.108334_bib9","doi-asserted-by":"crossref","first-page":"694","DOI":"10.1038\/leu.2017.273","article-title":"Activation of RHOA-VAV1 signaling in angioimmunoblastic T-cell lymphoma","volume":"32","author":"Fujisawa","year":"2018","journal-title":"Leukemia"},{"issue":"15","key":"10.1016\/j.leukres.2026.108334_bib10","doi-asserted-by":"crossref","first-page":"1741","DOI":"10.1182\/blood-2015-05-644591","article-title":"IDH2R172 mutations define a unique subgroup of patients with angioimmunoblastic T-cell lymphoma","volume":"126","author":"Wang","year":"2015","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2026.108334_bib11","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2023.1177590","article-title":"J. Angioimmunoblastic T-cell lymphoma and correlated neoplasms with T-cell follicular helper phenotype: from molecular mechanisms to therapeutic advances","volume":"13","author":"Lage","year":"2023","journal-title":"Front. Oncol."},{"key":"10.1016\/j.leukres.2026.108334_bib12","article-title":"Recent Update of HDAC Inhibitors in Lymphoma","volume":"8","author":"Chen","year":"2020","journal-title":"Front. Cell. Dev. Biol."},{"issue":"5","key":"10.1016\/j.leukres.2026.108334_bib13","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1111\/j.1365-2141.2009.08003.x","article-title":"Advances in the understanding and management of angioimmunoblastic T-cell lymphoma","volume":"148","author":"de Leval","year":"2010","journal-title":"Br. J. Haematol."},{"issue":"2","key":"10.1016\/j.leukres.2026.108334_bib14","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1016\/j.ccell.2023.01.003","article-title":"IDH2 and TET2 mutations synergize to modulate T Follicular Helper cell functional interaction with the AITL microenvironment","volume":"41","author":"Leca","year":"2023","journal-title":"Cancer Cell."},{"issue":"11","key":"10.1016\/j.leukres.2026.108334_bib15","doi-asserted-by":"crossref","DOI":"10.1016\/j.celrep.2023.113322","article-title":"\u03b21 integrin signaling governs necroptosis via the chromatin-remodeling factor CHD4","volume":"42","author":"Sun","year":"2023","journal-title":"Cell. Rep."},{"issue":"18","key":"10.1016\/j.leukres.2026.108334_bib16","doi-asserted-by":"crossref","first-page":"1937","DOI":"10.1182\/blood.2022015451","article-title":"Clonal germinal center B cells function as a niche for T-cell lymphoma","volume":"140","author":"Fujisawa","year":"2022","journal-title":"Blood"},{"issue":"9","key":"10.1016\/j.leukres.2026.108334_bib17","doi-asserted-by":"crossref","first-page":"270","DOI":"10.31083\/j.fbl2709270","article-title":"Spatial Transcriptomics Analysis Reveals that CCL17 and CCL22 are Robust Indicators of a Suppressive Immune Environment in Angioimmunoblastic T Cell Lymphoma (AITL)","volume":"27","author":"Du","year":"2022","journal-title":"Front. Biosci. (Landmark Ed."},{"issue":"1","key":"10.1016\/j.leukres.2026.108334_bib18","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1038\/s41408-024-01199-0","article-title":"Single-cell transcriptomic and spatial analysis reveal the immunosuppressive microenvironment in relapsed\/refractory angioimmunoblastic T-cell lymphoma","volume":"14","author":"Zhu","year":"2024","journal-title":"Blood Cancer J."},{"issue":"1","key":"10.1016\/j.leukres.2026.108334_bib19","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1186\/s13027-024-00627-x","article-title":"An exploratory study on the differential diagnostic indicators between adult systemic EBV-positive T-cell lymphoproliferative disorders and angioimmunoblastic T-cell lymphoma with multiple EBV infections","volume":"20","author":"Zheng","year":"2025","journal-title":"Infect. Agent. Cancer"},{"key":"10.1016\/j.leukres.2026.108334_bib20","doi-asserted-by":"crossref","first-page":"2335","DOI":"10.2147\/OTT.S189825","article-title":"Comparison of CHOP vs CHOPE for treatment of peripheral T-cell lymphoma: a meta-analysis","volume":"12","author":"Deng","year":"2019","journal-title":"Onco Targets Ther."},{"issue":"18","key":"10.1016\/j.leukres.2026.108334_bib21","doi-asserted-by":"crossref","first-page":"3418","DOI":"10.1182\/blood-2010-02-270785","article-title":"Treatment and prognosis of mature T-cell and NK-cell lymphoma: an analysis of patients with T-cell lymphoma treated in studies of the German High-Grade Non-Hodgkin Lymphoma Study Group","volume":"116","author":"Schmitz","year":"2010","journal-title":"Blood"},{"issue":"11","key":"10.1016\/j.leukres.2026.108334_bib22","doi-asserted-by":"crossref","first-page":"e972","DOI":"10.1016\/j.clml.2022.07.009","article-title":"Real-World Efficacy of 5-Azacytidine as Salvage Chemotherapy for Angioimmunoblastic T-cell Lymphoma","volume":"22","author":"Yoon","year":"2022","journal-title":"Clin. Lymphoma Myeloma Leuk."},{"issue":"11","key":"10.1016\/j.leukres.2026.108334_bib23","doi-asserted-by":"crossref","first-page":"1393","DOI":"10.1016\/j.medj.2024.07.007","article-title":"A prospective phase 2 study of combination epigenetic therapy against relapsed\/refractory peripheral T cell lymphoma","volume":"5","author":"Ding","year":"2024","journal-title":"Med"},{"issue":"5","key":"10.1016\/j.leukres.2026.108334_bib24","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1016\/j.clml.2024.11.015","article-title":"A Phase I Study of Romidepsin in Combination With Gemcitabine, Oxaliplatin, and Dexamethasone in Patients With Relapsed or Refractory Aggressive Lymphomas Enriched for T-Cell Lymphomas","volume":"25","author":"Foley","year":"2025","journal-title":"Clin. Lymphoma Myeloma Leuk."},{"issue":"3","key":"10.1016\/j.leukres.2026.108334_bib25","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1200\/JCO.21.01815","article-title":"Romidepsin Plus CHOP Versus CHOP in Patients With Previously Untreated Peripheral T-Cell Lymphoma: Results of the Ro-CHOP Phase III Study (Conducted by LYSA)","volume":"40","author":"Bachy","year":"2022","journal-title":"J. Clin. Oncol."},{"issue":"12","key":"10.1016\/j.leukres.2026.108334_bib26","doi-asserted-by":"crossref","first-page":"5527","DOI":"10.1007\/s00277-024-06063-6","article-title":"Comparison of tucidinostat with CHOP-like versus CHOP-like in first-line treatment of peripheral T-cell lymphoma: a single-center real-world study","volume":"103","author":"Wen","year":"2024","journal-title":"Ann. Hematol."},{"issue":"10","key":"10.1016\/j.leukres.2026.108334_bib27","doi-asserted-by":"crossref","first-page":"1159","DOI":"10.1182\/blood.2022016862","article-title":"An open-label, single-arm phase 2 trial of valemetostat for relapsed or refractory adult T-cell leukemia\/lymphoma","volume":"141","author":"Izutsu","year":"2023","journal-title":"Blood"},{"issue":"6","key":"10.1016\/j.leukres.2026.108334_bib28","doi-asserted-by":"crossref","first-page":"1100","DOI":"10.1080\/10428194.2025.2455489","article-title":"Results from an open-label phase 2a study of cerdulatinib, a dual spleen tyrosine kinase\/janus kinase inhibitor, in relapsed\/refractory peripheral T-cell lymphoma","volume":"66","author":"Horwitz","year":"2025","journal-title":"Leuk. Lymphoma"},{"issue":"1","key":"10.1016\/j.leukres.2026.108334_bib29","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/S1470-2045(23)00589-2","article-title":"Golidocitinib, a selective JAK1 tyrosine-kinase inhibitor, in patients with refractory or relapsed peripheral T-cell lymphoma (JACKPOT8 Part B): a single-arm, multinational, phase 2 study","volume":"25","author":"Song","year":"2024","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.leukres.2026.108334_bib30","article-title":"Safety and efficacy of dual PI3K-\u03b4, \u03b3 inhibitor, duvelisib in patients with relapsed or refractory lymphoid neoplasms: A systematic review and meta-analysis of prospective clinical trials","volume":"13","author":"Wang","year":"2022","journal-title":"Front. Immunol."},{"issue":"16","key":"10.1016\/j.leukres.2026.108334_bib31","doi-asserted-by":"crossref","first-page":"4286","DOI":"10.1182\/bloodadvances.2025016347","article-title":"Real-world evidence of duvelisib and romidepsin in relapsed\/refractory peripheral and cutaneous T-cell lymphomas","volume":"9","author":"Ford","year":"2025","journal-title":"Blood Adv."},{"issue":"20","key":"10.1016\/j.leukres.2026.108334_bib32","doi-asserted-by":"crossref","first-page":"3095","DOI":"10.1182\/blood-2013-12-542142","article-title":"Objective responses in relapsed T-cell lymphomas with single-agent brentuximab vedotin","volume":"123","author":"Horwitz","year":"2014","journal-title":"Blood"},{"issue":"10168","key":"10.1016\/j.leukres.2026.108334_bib33","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1016\/S0140-6736(18)32984-2","article-title":"Brentuximab Vedotin with Chemotherapy for CD30-Positive Peripheral T-cell Lymphoma (ECHELON-2): a global, double-blind, randomised, phase 3 trial","volume":"393","author":"Horwitz","year":"2019","journal-title":"Lancet"},{"key":"10.1016\/j.leukres.2026.108334_bib34","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1182\/blood-2025-155","volume":"146","author":"Thiruvengadam","year":"2025","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2026.108334_bib35","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2024.1410638","article-title":"A combination of 5-azacytidine and nivolumab is a potentially effective rescue therapy in relapsed\/refractory AITL","volume":"15","author":"Ricard","year":"2024","journal-title":"Front. Immunol."},{"issue":"1","key":"10.1016\/j.leukres.2026.108334_bib36","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1186\/s12967-026-07967-9","article-title":"CD30 CAR-T cells in combination with anti-PD-1 camrelizumab in relapsed\/refractory CD30+ lymphomas","volume":"24","author":"Yu","year":"2026","journal-title":"J. Transl. Med."},{"key":"10.1016\/j.leukres.2026.108334_bib37","doi-asserted-by":"crossref","unstructured":"Ishitsuka K., Yasukawa T., Tsuji Y. Safety and effectiveness of mogamulizumab in relapsed or refractory CC chemokine receptor 4-positive peripheral T-cell lymphoma and relapsed or refractory cutaneous T-cell lymphoma: A post-marketing surveillance in Japan. doi:10.1002\/hon.3292.","DOI":"10.1002\/hon.3292"},{"issue":"2","key":"10.1016\/j.leukres.2026.108334_bib38","doi-asserted-by":"crossref","DOI":"10.1002\/hem3.70313","article-title":"Autologous stem cell transplantation in major T-cell lymphoma entities: An analysis by the EBMT Lymphoma Working Party","volume":"10","author":"Shumilov","year":"2026","journal-title":"Hemasphere"},{"issue":"1","key":"10.1016\/j.leukres.2026.108334_bib39","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1186\/s13045-026-01783-w","article-title":"Allogeneic stem cell transplantation for major T-cell lymphoma entities: an analysis of the EBMT-lymphoma working party","volume":"19","author":"Shumilov","year":"2026","journal-title":"J. Hematol. Oncol."},{"issue":"5","key":"10.1016\/j.leukres.2026.108334_bib40","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1002\/ajh.26499","article-title":"Chidamide plus prednisone, etoposide, and thalidomide for untreated angioimmunoblastic T-cell lymphoma in a Chinese population: A multicenter phase II trial","volume":"97","author":"Wang","year":"2022","journal-title":"Am. J. Hematol."},{"issue":"13","key":"10.1016\/j.leukres.2026.108334_bib41","doi-asserted-by":"crossref","first-page":"1576","DOI":"10.1097\/CM9.0000000000002836","article-title":"Chidamide plus prednisone, cyclophosphamide, and thalidomide for relapsed or refractory peripheral T-cell lymphoma: A multicenter phase II trial","volume":"137","author":"Liang","year":"2024","journal-title":"Chin. Med. J. (Engl. )"},{"issue":"1","key":"10.1016\/j.leukres.2026.108334_bib42","doi-asserted-by":"crossref","first-page":"1206","DOI":"10.1038\/s41467-025-56506-5","article-title":"EZH2 serves as a viable therapeutic target for myeloma-induced osteolytic bone destruction","volume":"16","author":"Liu","year":"2025","journal-title":"Nat. Commun."},{"issue":"19","key":"10.1016\/j.leukres.2026.108334_bib43","doi-asserted-by":"crossref","first-page":"2983","DOI":"10.1182\/blood-2014-07-584953","article-title":"Immunohistochemistry as a valuable tool to assess CD30 expression in peripheral T-cell lymphomas: high correlation with mRNA levels","volume":"124","author":"Bossard","year":"2014","journal-title":"Blood"},{"issue":"8","key":"10.1016\/j.leukres.2026.108334_bib44","doi-asserted-by":"crossref","first-page":"e81","DOI":"10.3324\/haematol.2013.084913","article-title":"CD30 expression in peripheral T-cell lymphomas","volume":"98","author":"Sabattini","year":"2013","journal-title":"Haematologica"},{"issue":"7","key":"10.1016\/j.leukres.2026.108334_bib45","doi-asserted-by":"crossref","first-page":"3745","DOI":"10.1007\/s00277-025-06507-7","article-title":"Brentuximab vedotin plus CHP-like regimen for the first-line treatment of PTCL patients: a real-world single center study","volume":"104","author":"Guan","year":"2025","journal-title":"Ann. Hematol."},{"issue":"6","key":"10.1016\/j.leukres.2026.108334_bib46","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2022-004984","article-title":"Nivolumab in patients with relapsed or refractory peripheral T-cell lymphoma: modest activity and cases of hyperprogression","volume":"10","author":"Bennani","year":"2022","journal-title":"J. Immunother. Cancer"},{"issue":"1","key":"10.1016\/j.leukres.2026.108334_bib47","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1186\/s13287-021-02595-0","article-title":"CAR-T cell therapy in T-cell malignancies: Is success a low-hanging fruit?","volume":"12","author":"Safarzadeh Kozani","year":"2021","journal-title":"Stem Cell. Res. Ther."},{"issue":"1","key":"10.1016\/j.leukres.2026.108334_bib48","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1186\/s13046-024-03179-5","article-title":"vivo CAR T cell therapy against angioimmunoblastic T cell lymphoma","volume":"43","author":"Krug","year":"2024","journal-title":"J. Exp. Clin. Cancer Res."},{"issue":"9","key":"10.1016\/j.leukres.2026.108334_bib49","doi-asserted-by":"crossref","first-page":"1009","DOI":"10.1182\/blood.2021015114","article-title":"Impact of etoposide and ASCT on survival among patients aged <65 years with stage II to IV PTCL: a population-based cohort study","volume":"140","author":"Brink","year":"2022","journal-title":"Blood"},{"issue":"19","key":"10.1016\/j.leukres.2026.108334_bib50","first-page":"2646","article-title":"A randomized phase 3 trial of autologous vs allogeneic transplantation as part of first-line therapy in poor-risk peripheral T-NHL","volume":"137","author":"Schmitz","year":"2021","journal-title":"Blood"},{"issue":"11","key":"10.1016\/j.leukres.2026.108334_bib51","first-page":"952","article-title":"[Comparison of allogeneic or autologous hematopoietic stem cell transplant for high-risk peripheral T cell lymphomas]","volume":"37","author":"Wang","year":"2016","journal-title":"Zhonghua Xue Ye Xue Za Zhi"},{"issue":"4","key":"10.1016\/j.leukres.2026.108334_bib52","doi-asserted-by":"crossref","first-page":"3987","DOI":"10.1002\/cam4.5248","article-title":"Clinicopathologic characteristics, outcomes, and prognostic factors of angioimmunoblastic T-cell lymphoma in China","volume":"12","author":"Wei","year":"2023","journal-title":"Cancer Med."},{"key":"10.1016\/j.leukres.2026.108334_bib53","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2025.1580370","article-title":"Real-world data on clinical outcomes and validation of prognostic models for angioimmunoblastic T-cell lymphoma: a multicentric retrospective study in Southern China","volume":"15","author":"Xiang","year":"2025","journal-title":"Front. Oncol."},{"issue":"3","key":"10.1016\/j.leukres.2026.108334_bib54","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1182\/blood.2020010387","article-title":"Outcomes and prognostic factors in angioimmunoblastic T-cell lymphoma: final report from the international T-cell Project","volume":"138","author":"Advani","year":"2021","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.leukres.2026.108334_bib55","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1007\/s12288-024-01767-1","article-title":"Prognostic Utility of a Novel Prognostic Model Consisting of Age, CRP, Ki67, and POD24 in Patients with Angioimmunoblastic T-Cell Lymphoma","volume":"40","author":"Wang","year":"2024","journal-title":"Indian. J. Hematol. Blood Transfus."},{"issue":"20","key":"10.1016\/j.leukres.2026.108334_bib56","first-page":"4198","article-title":"Next-generation sequencing-based monitoring of circulating tumor DNA reveals clonotypic heterogeneity in untreated PTCL","volume":"5","author":"Miljkovic","year":"2021","journal-title":"Blood Adv."},{"key":"10.1016\/j.leukres.2026.108334_bib57","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1186\/s12964-025-02438-y","article-title":"Clinical implications of ctDNA-based minimal residual disease detection in newly diagnosed peripheral T-cell lymphoma: a single-center cohort study","volume":"23","author":"Liang","year":"2025","journal-title":"Cell. Commun. Signal."}],"container-title":["Leukemia Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0145212626001785?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0145212626001785?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T03:43:41Z","timestamp":1791258221000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0145212626001785"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,12]]},"references-count":57,"alternative-id":["S0145212626001785"],"URL":"https:\/\/doi.org\/10.1016\/j.leukres.2026.108334","relation":{},"ISSN":["0145-2126"],"issn-type":[{"value":"0145-2126","type":"print"}],"subject":[],"published":{"date-parts":[[2026,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Advances in diagnosis and treatment of angioimmunoblastic T-cell lymphoma","name":"articletitle","label":"Article Title"},{"value":"Leukemia Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.leukres.2026.108334","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"108334"}}